RETRACTED: Efficacy of novel antibody-based drugs against rhinovirus infection: In vitro and in vivo results
File(s)
Published version (RETRACTED)
Author(s)
Type
Journal Article
Abstract
Rhinoviruses (RVs) cause the common cold and are associated with exacerbations of chronic inflammatory respiratory diseases, especially asthma and chronic obstructive pulmonary disease (COPD). We have assessed the antiviral drugs Anaferon for Children (AC) and Ergoferon (containing AC as one of the active pharmaceutical ingredients) in in vitro and in vivo experimental models, in order to evaluate their anti-rhinoviral and immunomodulatory potential. HeLa cells were pretreated with AC, and levels of the interferon-stimulated gene (ISG), 2 0-5 0-oligoadenylate synthetase 1 (OAS1-A) and viral replication were analyzed. In a mouse model of RV-induced exacerbation of allergic airway inflammation we administered Ergoferon and analyzed its effect on type I (IFN-b), type II (IFN-g) and type III (IFN-l) IFNs induction, cell counts in bronchoalveolar lavage (BAL), cytokine (interleukin (IL)-4; IL-6) and chemokine (CXCL10/IP-10; CXCL1/KC) levels. It was shown that AC increased OAS1-А production and significantly decreased viral replication in vitro. Increased IFNs expression together with reduced neutrophils/lymphocytes recruitment and correlated IL-4/IL-6 declination was demonstrated for Ergoferon in vivo. However, there was no effect on examined chemokines. We conclude that AC and Ergoferon possess effects against RV infection and may have potential as novel therapies against RV-induced exacerbations of asthma.
Date Issued
2017-06-01
Date Acceptance
2017-03-23
Citation
Antiviral Research, 2017, 142, pp.185-192
ISSN
0166-3542
Publisher
Elsevier
Start Page
185
End Page
192
Journal / Book Title
Antiviral Research
Volume
142
Copyright Statement
© 2017, Elsevier. Licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International http://creativecommons.org/licenses/by-nc-nd/4.0/
Identifier
http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000401203100019&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=1ba7043ffcc86c417c072aa74d649202
Subjects
AIRWAY INFLAMMATION
Antibodies
ASTHMA EXACERBATIONS
CELL ENTRY
CHILDREN
CONTROLLED-TRIAL
Cytokine
Human rhinovirus infection
INTERFERON
Interferon stimulated genes
Life Sciences & Biomedicine
NEUTROPHILS
PATHOGENESIS
Pharmacology & Pharmacy
Science & Technology
VIRAL-INFECTION
Virology
VIRUS
Publication Status
Published
Date Publish Online
2017-03-27